Markus Joerger

19PUBLICATIONS
114CO-AUTHORS
PharmacogenomicsPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jun 12, 2026
Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.

|Mar 08, 2026
Review of Existing Approaches and Potential Role of Pharmacometrics in the Interpretation of Prognostic Circulating Serum Biomarkers in Advanced NSCLC.

Francis Williams Ojara, Yomna M Nassar, Kimberly Geiger

|Nov 18, 2025
TLD-1, a Novel Liposomal Doxorubicin, in Patients with Solid Tumors: Comparative Pharmacokinetics and Final Results of a Multicenter Phase 1 Study (SAKK 65/16).

Marian Klose, Ilaria Colombo, Katrin Gobat

|Jun 14, 2025
Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects.

Timothy A Yap, David S P Tan, Anastasios Stathis

|Mar 11, 2025
Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial.

Ulrich Güller, Stefanie Hayoz, Daniel Horber

|Jul 29, 2024
Combination Therapy with Immune Checkpoint Inhibitors and Histone Deacetylase Inhibitors or Alkylating Agents.

Markus Joerger, Kira-Lee Koster, Tomas Janik

Pageof 4

Frequent Collaborators

4 joint publications

Anna Mueller-Schoell

4 joint publications

Robin Michelet

3 joint publications

Stefanie Hayoz

2 joint publications

Francis Williams Ojara